Therapeutic Drug Screening
Therapeutic Drug Screening - Related Videos
11:28
3D Microtissues for Injectable Regenerative Therapy and High-throughput Drug Screening
0 Views •
Cited by 7 •
2017
This protocol describes the fabrication of elastic 3D macroporous microcryogels by integrating microfabrication with cryogelation technology. Upon loading with cells, 3D microtissues are generated, which can be readily injected in vivo to facilitate regenerative therapy or assembled into arrays for in vitro high-throughput drug screening.
05:54
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
0 Views •
Cited by 10 •
2018
Across a wide variety of disease indications, more physiologically relevant models are being developed and implemented into drug discovery programs. The new model system described here demonstrates how three-dimensional tumor spheroids can be cultured and screened in a high-throughput 1536-well plate-based system to search for new oncology drugs.
05:04
An Ultrasound-Guided Injection of Therapeutic Drugs into Human Salivary Glands
0 Views •
2025
The video demonstrates an ultrasound-guided injection technique for administering therapeutic drugs into the salivary glands of a human patient.
01:21
Antipsychotic Drugs: Therapeutic Uses and Side Effects
0 Views •
2024
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia. Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
01:26
Therapeutic Drug Monitoring: Drug Analysis Methods
0 Views •
2025
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
FAQs
Dose-response comparisons show how biological effects change as the concentration of a candidate medicine increases. Researchers can compare the concentration associated with a desired response against changes linked to toxicity, helping distinguish stronger activity from undesirable effects. This analysis supports judgments about potency and helps prioritize compounds for further investigation rather than relying on a single test concentration.
The biological model determines which aspects of drug action can be observed. Cells, tissues, microorganisms, and model organisms provide progressively different levels of biological representation, while more physiologically representative systems can clarify whether an effect remains meaningful beyond a rapid assay. Comparing results across models helps connect molecular activity with broader therapeutic outcomes.
Selectivity is examined by comparing a compound’s effects across relevant biological responses, rather than measuring only one desired outcome. A candidate that changes a target pathway or inhibits growth may still produce unwanted effects at different concentrations. Evaluating potency, pathway activity, viability, and toxicity together gives a more informative picture of whether activity is focused or broadly disruptive.
A common progression begins with rapid, high-throughput assays that allow many candidate compounds to be compared efficiently. Compounds showing promising responses can then be examined in more physiologically representative cells, tissues, microorganisms, or model organisms. This staged workflow narrows the candidate set while adding biological context needed to assess potency, selectivity, mechanism, and safety.
Useful measurements include cell or organism viability, pathway activity, growth inhibition, and changes in biomarkers. The appropriate readout depends on the biological question and the model being tested. Combining several response types can show whether a compound produces the intended effect, alters a relevant biological pathway, or generates signals associated with toxicity.
Screening informs several decisions after candidate activity has been observed. It can guide lead optimization by identifying compounds with more favorable potency or selectivity, support treatment selection by comparing biological responses, and contribute to preclinical safety assessment through toxicity-focused measurements. In biology, these results also help link molecular targets and mechanisms of action with therapeutic outcomes.